Nanoscope Therapeutics

Research Continuum Graphic. All sections shown in grey: Basic & Translational, Pre-clinical, Clinical trials: Phase I, Phase II, Phase III, Treatments-Phase IV

Nanoscope Therapeutics Inc. is a clinical-stage biotechnology company that is developing gene-agnostic therapies for individuals with retinal degenerative diseases. In October 2022, the company announced the FDA has granted Fast Track Designation to their asset MCO-010, an optogenetic monotherapy, that through injection can be a treatment for retinitis pigmentosa (RP). Having a Fast Track Designation is significant because it expedites the review process of a novel therapy by allowing for increased communication with the FDA regarding regulatory hurdles.

In March 2023, Nanoscope announced positive topline results from its Phase 2b RESTORE Trial of MCO-010 for the treatment of retinitis pigmentosa.

Nanoscope Therapeutics website

Clinicaltrials.gov ID NCT04945772

Nanoscope Related Science News

March 30, 2023

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa

October 10, 2022

Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Retinitis Pigmentosa

June 23, 2021

Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company, has recently announced that one of its drugs is approved for Phase 2b clinical trial.